Evidence map›Paper›PMID 40494851›Full record

ArticleSignal transduction and targeted therapy2025

Mitsugumin 53 drives stem cell differentiation easing intestinal injury and inflammation.

Yumeng Pei, Meng Fang, Hong-Kun Wu, Qionghua Cui, Li Quan, Xiaochuan Li, Keyi Zhang, Peng Xie, Peng Jiang, Yuan Liu and 6 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yumeng Pei *State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Meng Fang *State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.ORCID 0009-0000-0122-416X
Hong-Kun WuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.ORCID 0000-0002-9459-6583
Qionghua CuiState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.ORCID 0000-0001-5285-5260
Li QuanState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Xiaochuan LiState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Keyi ZhangState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Peng XieState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Peng JiangState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Yuan LiuThe State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, 100084, China.
Meimei HuangThe State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, 100084, China.
Fengxiang LvState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Xiaomin HuState Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100730, Beijing, China.
Ye-Guang ChenThe State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, 100084, China.ORCID 0000-0002-6701-0065
Xinli HuState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China. huxxx025@pku.edu.cn.ORCID 0000-0003-4911-5354
Rui-Ping XiaoState Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China. xiaor@pku.edu.cn.ORCID 0000-0003-2448-409X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81630008National Natural Science Foundation of China (National Science Foundation of China) 81770376National Natural Science Foundation of China (National Science Foundation of China) 81790621National Science Foundation of China | Key Programme 2018YFA0507603National Science Foundation of China | Key Programme 2018YFA0800701National Science Foundation of China | Key Programme 2022YFA1303003
6 · The paper itself

Abstract

Emerging evidence suggests that priming intestinal stem cells (ISCs) towards secretory progenitor cells is beneficial for maintaining gut homeostasis against inflammatory bowel disease (IBD). However, the mechanism driving such biased lineage commitment remains elusive. Here we show that MG53, also named as TRIM72, prompts ISCs to secretory lineages via upregulating peroxisome proliferator-activated receptor α (PPARα), thus maintaining intestinal epithelium integrity against noxious insults. Using genetic mouse models, we found that MG53 deficiency leads to exacerbated intestinal damage caused by various injuries in mice, whereas MG53 overexpression in ISCs is sufficient to ameliorate such damage. Mechanistically, MG53 promoted asymmetric division of ISCs to generate more progenitor cells of secretory lineages via activating PPARα signaling. Specifically, MG53 overexpression induced PPARα expression at transcriptional level and concomitantly increased PPARα activity by elevating the contents of a panel of unsaturated fatty acids in the intestine that serve as potent endogenous agonists of PPARα. Furthermore, genetic ablation or pharmacological inhibition of PPARα abolished the protective effects of MG53. These findings reveal a crucial role of MG53-PPARα axis in driving the secretory lineage commitment of ISCs, especially during injury response, highlighting the important therapeutic potential of targeting MG53-PPARα signaling for IBD treatment and marking PPARα agonists as novel therapies for IBD caused by various etiologies.

Indexed as

Cell DifferentiationInflammationInflammatory Bowel DiseasesIntestinal MucosaPPAR alphaStem CellsAnimalsHumansIntestinesMiceSignal TransductionPPAR alphaPpara protein, mouse

Identifiers

PMID40494851
PMCPMC12152187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.